Evidence map›Paper›PMID 33223405›Full record

ArticleNutrition, metabolism, and cardiovascular diseases : NMCD2021

Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily.

G Antonio Silverii, Matteo Monami, Achille Cernigliaro, Enrica Vigneri, Valentina Guarnotta, Salvatore Scondotto, Vincenza A Allotta, Michela Conti, Carla Giordano, Edoardo Mannucci

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 15 pooled it
1.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 15 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes.Translational research : the journal of laboratory and clinical medicine · 2022
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

G Antonio SilveriiExperimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Italy. Electronic address: antonio.silverii@gmail.com.
Matteo MonamiExperimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Italy.
Achille CernigliaroHealth Activities and Epidemiologic Observatory Division, Health Department, Sicily Region, Italy.
Enrica VigneriHealth Promotion, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", PROMISE, University of Palermo, Italy.
Valentina GuarnottaHealth Promotion, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", PROMISE, University of Palermo, Italy.
Salvatore ScondottoHealth Activities and Epidemiologic Observatory Division, Health Department, Sicily Region, Italy.
Vincenza A AllottaHealth Activities and Epidemiologic Observatory Division, Health Department, Sicily Region, Italy.
Michela ContiHealth Promotion, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", PROMISE, University of Palermo, Italy.
Carla GiordanoHealth Promotion, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", PROMISE, University of Palermo, Italy.
Edoardo MannucciExperimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Italy.
University of Palermo · ITUniversity of Florence · ITEuropean Society for Sexual Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsDiabetes mellitus (DM) has been associated with higher incidence of severe cases of COVID-19 in hospitalized patients, but it is unknown whether DM is a risk factor for the overall COVID-19 incidence. The aim of present study was to investigate whether there is an association of DM with COVID-19 prevalence and case fatality, and between different DM medications and risk for COVID-19 infection and death. METHODS AND

resultsretrospective observational study on all SARS-CoV-2 positive (SARS-CoV-2

conclusionsin Sicily, DM was not a risk factor for COVID-19 infection, whereas it was associated with a higher case fatality.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCOVID-19Diabetes MellitusFemaleHumansHypoglycemic AgentsIncidenceInfantMaleMiddle AgedPrevalenceHypoglycemic AgentsCOVID-19 case fatalityCOVID-19 incidenceDiabetes mellitus

Identifiers

PMID33223405
PMCPMC7528967
OpenAlexW3091602118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.